- Previous Close
0.1090 - Open
0.1110 - Bid 0.1050 x --
- Ask 0.1190 x --
- Day's Range
0.1100 - 0.1110 - 52 Week Range
0.1090 - 0.4220 - Volume
0 - Avg. Volume
0 - Market Cap (intraday)
49.086M - Beta (5Y Monthly) 0.66
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; SlypSeal Flex, an electrosurgical haemostasis device; and SpydrBlade Flex, a bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues. In addition, it provides endotherapy accessories comprising ScopeSnare, an energy-based polypectomy snares; ScopeSnare Cold, a cutting wire for use in endoscopically in the removal of diminutive, sessile and pedunculated polyps, and tissue from within the gastrointestinal (GI) tract; ScopeClip for clip placement in the digestive tract; ScopeInject for endoscopic injection into GI mucosa; ScoprGrasp, a disposable grasping forceps for digestive and bronchial endoscopy; ScopeBite, a portfolio of digestive biopsy forceps; and other products for gastroenterology, pulmonology, and urology. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, the United Kingdom.
www.creomedical.comRecent News: 1RC.SG
View MorePerformance Overview: 1RC.SG
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1RC.SG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1RC.SG
View MoreValuation Measures
Market Cap
48.64M
Enterprise Value
53.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.11
Price/Book (mrq)
0.81
Enterprise Value/Revenue
1.52
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-73.93%
Return on Assets (ttm)
-20.09%
Return on Equity (ttm)
-38.49%
Revenue (ttm)
30.3M
Net Income Avi to Common (ttm)
-22.4M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
9.8M
Total Debt/Equity (mrq)
29.96%
Levered Free Cash Flow (ttm)
-14.95M